itraconazole has been researched along with ciclopirox in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 16 (53.33) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Baran, R | 1 |
| De Doncker, P; Dubois, DJ; Eggleston, A; Gupta, AK; Haneke, E; Tormans, G; Van Doorslaer, EK; Van Rossem, K | 1 |
| Damianov, L; Ivanov, S; Novachkov, V | 1 |
| Gupta, AK | 2 |
| Czaika, V; Schmalreck, A; Schultze, W; Sterry, W; Tietz, HJ | 1 |
| Amaya, K; Arikian, S; Casciano, J; Doyle, J; Haspel, M; Kahler, K; Shear, N | 1 |
| Jones, ED | 1 |
| Gupta, AK; Kohli, Y | 1 |
| Reinel, D | 1 |
| Armstrong, D; Bondar, G; Werschler, WP | 1 |
| Macura, AB; Pawlik, B; Szczepko, I | 1 |
| Sellart-Altisent, M; Torres-Rodríguez, JM | 1 |
| de Assis Santos, D; Figueiredo, VT; Hamdan, JS; Resende, MA | 1 |
| Fierlbeck, G; Guenova, E; Hoetzenecker, W; Röcken, M; Schaller, M | 1 |
| Fischer, M; Marsch, WC; Meykadeh, N; Schaller, M; Waltermann, K | 1 |
| de Berker, D | 1 |
| Budihardja, D; Freund, V; Mayser, P | 1 |
| de Carvalho, L; de Oliveira, JC; Hering, B; Jimenez, PA; Mendonça, I; Stallone, C; Val, A | 1 |
| Vera-Cabrera, L; Welsh, E; Welsh, O | 1 |
| Bulgheroni, A; Celandroni, F; Ghelardi, E; Gueye, SA; Mailland, F; Salvetti, S; Senesi, S | 1 |
| Pajaziti, L; Vasili, E | 1 |
| Rosen, T; Stein Gold, LF | 1 |
| Chanda, S; Coronado, D; Del Rosso, J; Zane, LT | 1 |
| Liu, X; Ma, W; Yang, J | 1 |
| Chakrabarti, A; Dogra, S; Mushtaq, K; Narang, T; Paul, RA; Rudramurthy, SM; Shankarnarayan, SA; Shaw, D | 1 |
| Lipner, SR; Scher, RK | 1 |
| Burmester, A; Ebert, A; Monod, M; Nenoff, P; Schaller, M; Stahl, M; Uhrlaß, S | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
10 review(s) available for itraconazole and ciclopirox
| Article | Year |
|---|---|
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Arthrodermataceae; Ciclopirox; Costs and Cost Analysis; Drug Costs; Economics, Pharmaceutical; Female; Fluconazole; Foot Dermatoses; Griseofulvin; Humans; Itraconazole; Male; Models, Economic; Naphthalenes; Onychomycosis; Pyridones; Randomized Controlled Trials as Topic; Terbinafine; United States | 2000 |
Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Drug Costs; Foot Dermatoses; Griseofulvin; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; United States | 2002 |
Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Topics: Adult; Antifungal Agents; Ciclopirox; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Foot Dermatoses; Hand Dermatoses; Humans; Itraconazole; Managed Care Programs; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; United States | 2003 |
Assessing treatment outcomes in toenail onychomycosis clinical trials.
Topics: Antifungal Agents; Ciclopirox; Clinical Trials as Topic; Foot Dermatoses; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome | 2004 |
Clinical practice. Fungal nail disease.
Topics: Administration, Oral; Administration, Topical; Aged; Antifungal Agents; Ciclopirox; Debridement; Diagnosis, Differential; Foot Dermatoses; Humans; Itraconazole; Male; Naphthalenes; Onychomycosis; Practice Guidelines as Topic; Pyridones; Terbinafine | 2009 |
Toenail onychomycosis in diabetic patients: issues and management.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Ciclopirox; Comorbidity; Diabetes Mellitus; Diabetic Foot; Drug Interactions; Drug Therapy, Combination; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Morpholines; Naphthalenes; Onychomycosis; Prevalence; Pyridones; Risk Factors; Terbinafine; Therapies, Investigational; Treatment Outcome | 2009 |
Onychomycosis.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Mitosporic Fungi; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Pyrimidines; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2010 |
Antifungal agents for onychomycosis: new treatment strategies to improve safety.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Chemical and Drug Induced Liver Injury; Ciclopirox; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2016 |
Onychomycosis: Treatment and prevention of recurrence.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Fluconazole; Humans; Itraconazole; Laser Therapy; Nanoparticles; Onychomycosis; Photochemotherapy; Plasma Gases; Prognosis; Pulse Therapy, Drug; Risk Factors; Secondary Prevention; Severity of Illness Index; Terbinafine; Triazoles | 2019 |
[Recurrent tinea corporis generalisata due to Terbinafine-resistant Trichophyton rubrum strain : Long-term treatment with super bioavailability itraconazole].
Topics: Aged, 80 and over; Biological Availability; Ciclopirox; Humans; Isoleucine; Itraconazole; Male; Squalene Monooxygenase; Terbinafine; Tinea | 2023 |
1 trial(s) available for itraconazole and ciclopirox
| Article | Year |
|---|---|
Treatment of Onychomycosis - a Clinical Study.
Topics: Antifungal Agents; Ciclopirox; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pulse Therapy, Drug; Pyridones; Terbinafine | 2015 |
19 other study(ies) available for itraconazole and ciclopirox
| Article | Year |
|---|---|
[New treatments of onychomycoses].
Topics: Administration, Topical; Antifungal Agents; Candidiasis; Ciclopirox; Fluconazole; Foot Dermatoses; Hand Dermatoses; Humans; Itraconazole; Ketoconazole; Morpholines; Onychomycosis; Pyridones | 1992 |
Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
Topics: Algorithms; Antifungal Agents; Ciclopirox; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Trees; Drug Administration Schedule; Drug Costs; Evaluation Studies as Topic; Follow-Up Studies; Foot Dermatoses; Germany; Health Resources; Humans; Itraconazole; Meta-Analysis as Topic; Naphthalenes; Onychomycosis; Paint; Practice Patterns, Physicians'; Pyridones; Sensitivity and Specificity; Terbinafine | 1996 |
[The treatment of acute mycotic colpitis with ciclopiroxolamine in patients using oral contraceptives].
Topics: Acute Disease; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Ciclopirox; Contraceptives, Oral; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Itraconazole; Pyridones; Vaginal Creams, Foams, and Jellies | 1997 |
[Antifungal susceptibility testing in chronically recurrent vaginal candidosis as basis for effective therapy].
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Chronic Disease; Ciclopirox; Female; Fluconazole; Flucytosine; Humans; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Pyridones; Pyrimidines; Terbinafine; Triazoles; Vaginitis; Voriconazole | 2000 |
Onychomycosis: current treatment options.
Topics: Antifungal Agents; Ciclopirox; Female; Humans; Itraconazole; Male; Middle Aged; Onychomycosis; Patient Education as Topic; Pyridones | 2003 |
In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.
Topics: Antifungal Agents; Arthrodermataceae; Ciclopirox; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Fungi; Humans; Itraconazole; Ketoconazole; Microbial Sensitivity Tests; Naphthalenes; Pyridones; Terbinafine | 2003 |
[Onychomycosis].
Topics: Antifungal Agents; Ciclopirox; Debridement; Diagnosis, Differential; Drug Therapy, Combination; Fluconazole; Griseofulvin; Humans; Imidazoles; Itraconazole; Morpholines; Mycological Typing Techniques; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Time Factors | 2004 |
[The susceptibility of Aspergillus and Penicillium to recent antimycotics].
Topics: Antifungal Agents; Aspergillus; Ciclopirox; Drug Resistance, Fungal; Itraconazole; Microbial Sensitivity Tests; Morpholines; Naphthalenes; Penicillium; Pyridones; Terbinafine | 2000 |
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
Topics: Antifungal Agents; Cellulitis; Ciclopirox; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Resistance, Multiple, Fungal; Foot Dermatoses; Fusarium; Humans; Imidazoles; Immunocompetence; Itraconazole; Male; Middle Aged; Mozambique; Onychomycosis; Pyridones; Pyrimidines; Recurrence; Toes; Travel; Triazoles; Urea; Voriconazole | 2006 |
Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections.
Topics: Antifungal Agents; Brazil; Candida; Candidiasis; Ciclopirox; Fluconazole; Hand Dermatoses; Humans; Itraconazole; Ketoconazole; Miconazole; Microbial Sensitivity Tests; Naphthalenes; Onychomycosis; Pyridones; Terbinafine | 2007 |
Tinea incognito hidden under apparently treatment-resistant pemphigus foliaceus.
Topics: Aged; Antifungal Agents; Azathioprine; Ciclopirox; Drug Resistance, Multiple; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Itraconazole; Pemphigus; Prednisolone; Pyridones; Tinea; Trichophyton | 2008 |
Bullous ulcerating tinea.
Topics: Adolescent; Antifungal Agents; Blister; Candidiasis; Ciclopirox; Female; Humans; Itraconazole; Pyridones; Tinea | 2009 |
[Melanonychia: The purpose of a case of ungual mycotization mimicking melanoma].
Topics: Aged; Antifungal Agents; Ciclopirox; Diagnosis, Differential; Humans; Itraconazole; Male; Mycoses; Nail Diseases; Phialophora; Pigmentation Disorders; Pyridones | 2010 |
Potential of Ergosterol synthesis inhibitors to cause resistance or cross-resistance in Trichophyton rubrum.
Topics: Antifungal Agents; Ciclopirox; Drug Resistance, Fungal; Ergosterol; Itraconazole; Microbial Sensitivity Tests; Morpholines; Naphthalenes; Pyridones; Terbinafine; Trichophyton | 2014 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles; United States | 2016 |
Primary cutaneous aspergillosis caused by Aspergillus.fumigatus in an immunocompetent patient: A case report.
Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Child; Ciclopirox; Dermatomycoses; Humans; Immunocompetence; Itraconazole; Male; Pyridones; Skin | 2017 |
Mutation in the Squalene Epoxidase Gene of Trichophyton interdigitale and Trichophyton rubrum Associated with Allylamine Resistance.
Topics: Allylamine; Antifungal Agents; Arthrodermataceae; Ciclopirox; Drug Resistance, Fungal; Fluconazole; Itraconazole; Microbial Sensitivity Tests; Morpholines; Squalene Monooxygenase; Terbinafine; Trichophyton; Voriconazole | 2018 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |